Immuno-Oncology

Latest News

kidney cancer
Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Blood draws © adobe.stock.com
Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

June 7th 2023

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023

FDA
Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

April 24th 2023

melanoma
mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023

Latest CME Events & Activities

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

2024 International Symposium of Gastrointestinal Oncology (ISGIO)

October 11-12, 2024

Register Now!

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

More News

© 2024 MJH Life Sciences

All rights reserved.